We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Moody Month

Status: Active

Nov 16th 2020 - Dec 16th 2020

Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

read more read less

Moody Month Rating Review

Pitch rating powered by CROWDRATING

Rated on 23/11/2020

Pitch Rated

54%

Insufficient Data

Management

84%

Product

77%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £5,486,592
    pre-money valuation

    1.79%
    equity available

    255
    investors

    £557
    pledge per investor

    10047636
    company number

    Active
    company status

    07/03/2016
    incorporated 8 years

    £3.04
    share price

    Previous Funding rounds
    28 Apr 24 Crowdcube £142,026 / 142% 53.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 84%

Skills 82%
Moody Month has a skilled and diverse team covering operations, marketing, platform development, and finance. Their Founder/CEO specialises in Event Planning, Live Events, Event Management, Relationship Marketing, Financial Analysis, and Mergers and Acquisitions. Their CTO is skilled in several Programming languages like C++, OpenGL, Python, and Unity3D. Their COO has skills to build the brand and increase brand awareness through Digital Marketing, Online Advertising, Brand Architecture, Brand Management, and Digital Media. Their Co-Founder/Nutritionist is skilled in Nutritional Counseling, Dietary Supplements, Holistic Health, Nutrition Education, and Clinical Nutrition. We note that the company has not appointed a finance head, and the responsibility for the same lies with the Founder/CEO.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £5,486,592
    pre-money valuation

    1.79%
    equity available

    255
    investors

    £557
    pledge per investor

    10047636
    company number

    Active
    company status

    07/03/2016
    incorporated 8 years

    £3.04
    share price

    Previous Funding rounds
    28 Apr 24 Crowdcube £142,026 / 142% 53.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph